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Abstract
Introduction Opioid prescribing is increasing in many countries. In Australia, there is limited research on
patterns of prescribing and access, or the outcomes associated with this use. The aim of this research
programme is to use national dispensing data to estimate opioid use and costs, including problematic or
extramedical use in the Australian population. Methods and analysis In a cohort of persons dispensed at least
one opioid in 2013, we will estimate monthly utilisation and costs of prescribed opioids, overall and according
to individual opioid formulations and strengths. In a cohort of new opioid users, commencing therapy
between 1 July 2009 and 31 December 2013, we will examine patterns of opioid use including initiation of
therapy, duration of treatment and concomitant use of opioids and other prescribed medicines. We will also
examine patterns of extramedical opioid use based on indicators including excess dosing, use of more than
one opioid concomitantly, doctor/pharmacy shopping and accelerated time to prescription refill. Ethics and
dissemination This protocol was approved by the NSW Population and Health Services Ethics Committee
(March 2014) and data access approved by the Department of Human Services External Review Evaluation
Committee ( June 2014). This will be one of the first comprehensive Australian studies with the capability to
investigate individual patterns of use and track extramedical use. In the first instance our analysis will be based
on 5 years of dispensing data but will be expanded with ongoing annual data updates. This research has the
capability to contribute significantly to pharmaceutical policy within Australia and globally. In particular, the
trajectory of extramedical prescription-opioid use has been the subject of limited research to date. The results
of this research will be published widely in general medical, pharmacoepidemiology, addiction and psychiatry
journals.
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ABSTRACT
Introduction: Opioid prescribing is increasing in many
countries. In Australia, there is limited research on
patterns of prescribing and access, or the outcomes
associated with this use. The aim of this research
programme is to use national dispensing data to
estimate opioid use and costs, including problematic or
extramedical use in the Australian population.
Methods and analysis: In a cohort of persons
dispensed at least one opioid in 2013, we will estimate
monthly utilisation and costs of prescribed opioids,
overall and according to individual opioid formulations
and strengths. In a cohort of new opioid users,
commencing therapy between 1 July 2009 and 31
December 2013, we will examine patterns of opioid
use including initiation of therapy, duration of
treatment and concomitant use of opioids and other
prescribed medicines. We will also examine patterns of
extramedical opioid use based on indicators including
excess dosing, use of more than one opioid
concomitantly, doctor/pharmacy shopping and
accelerated time to prescription refill.
Ethics and dissemination: This protocol was
approved by the NSW Population and Health Services
Ethics Committee (March 2014) and data access
approved by the Department of Human Services
External Review Evaluation Committee ( June 2014).
This will be one of the first comprehensive Australian
studies with the capability to investigate individual
patterns of use and track extramedical use. In the first
instance our analysis will be based on 5 years of
dispensing data but will be expanded with ongoing
annual data updates. This research has the capability to
contribute significantly to pharmaceutical policy within
Australia and globally. In particular, the trajectory of
extramedical prescription-opioid use has been the
subject of limited research to date. The results of this
research will be published widely in general medical,
pharmacoepidemiology, addiction and psychiatry
journals.
BACKGROUND
The global increase in prescribed opioid use
over the past 30 years has been well
documented.1–8 In Australia, between 1992 and
2007, there was a 300% increase in the number
of opioid prescriptions dispensed in the commu-
nity.5 In 2012, 7.4 million opioid prescriptions
were dispensed via the Pharmaceutical Benefits
Scheme (PBS), costing the Australian govern-
ment approximately $A271 million. In the 20-
year period 1992–2012, the Commonwealth of
Australia subsidised over $A2 billion in
Strengths and limitations of this study
▪ Using data on prescriptions reimbursed by the
Pharmaceutical Benefits Scheme (PBS), this
study will provide novel data on the patterns and
costs of opioid use, including extramedical use,
in the Australian population. This will provide the
most detailed information to date regarding
person-level patterns of opioid consumption in
Australia.
▪ The research programme is limited by:
– The extent to which these data reflect total
opioid consumption. The data set used in the
PBS data does not include private prescrip-
tions or over-the-counter opioids. In addition,
parts of the study will not capture low-cost
PBS-listed items dispensed to Australians
with the highest patient copayment threshold.
– Dispensing claims do not detail clinical infor-
mation, including indication for use, which
poses challenges given doses of opioids vary
depending on the nature of the pain being
managed. However, using complete PBS
history for each individual, we will be able to
identify patients with a recent cancer treat-
ment history.
– The absence of gold-standard proxy indica-
tors of extramedical opioid use. As such, we
will develop indicators through consultation
of the literature and feedback from expert
clinicians in the fields of pain, cancer and
addiction. Sensitivity analyses will be used to
establish whether our conclusions are
affected by variations in definitions.
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prescribed opioids, with oxycodone and morphine account-
ing for $A1.1 billion.9 Europe and the USA have seen even
larger increases in opioid dispensing than Australia.10
Despite the Australian government’s significant investment
in these medicines, we know little about the way they are
used in routine clinical care.
The observed global increase in opioid use can be
attributed, in part, to the broadening of regulatory and
subsidy approval of opioids to manage chronic non-
cancer pain; previously use was restricted to the manage-
ment of cancer pain. As opioid use has increased, so too
has the concern from healthcare professionals and the
public in relation to the harms of prolonged medical
use, including concerns about the appropriateness of
prescribing opioids long term and the risk of iatrogenic
dependence.11 The most serious risk associated with
opioid use is the harm related to opioid overdose. In the
USA, prescribed medicines account for more fatal and
non-fatal overdoses than illicit drugs.12 People dying
from opioid overdoses often use other medicines con-
comitantly such as benzodiazepines, antidepressants,
antipsychotics and psychostimulants,13 14 which may
further contribute to the risk of an adverse outcome. In
Australia, notable increases in reported opioid prescrip-
tions have occurred.5 This has been associated with hos-
pital separations for opioid poisoning, treatment
episodes3 9 and deaths attributed to pharmaceutical
opioids such as oxycodone.4 15
‘Extramedical use’ is defined as use not as directed by
a doctor.16 Among other things, it may include using
more than directed by the doctor; asking for escalating
doses; obtaining prescriptions from multiple doctors
without their knowledge; tampering with opioids and
taking opioids via routes other than intended (eg, snort-
ing or injecting).16 A 2010 Australian national survey
reported a 7.4% lifetime prevalence and 4.2% 12-month
prevalence of using medicines such as analgesics, seda-
tives/hypnotics, methadone, other opioids and steroids
when not medically indicated,17 equating to approxi-
mately 1 in 14 Australians engaging in extramedical use
of a prescribed medicine in their lifetime (with a higher
prevalence in younger age groups).
Observational cohort studies from the USA and
Europe have examined the natural history of opioid
analgesic use for chronic non-cancer pain.18 Small retro-
spective cohort studies have examined treatment dur-
ation, pain reduction, adverse drug events19 and
aberrant behaviours.20 Larger retrospective cohort
studies have examined the risk of overdose,21 the impact
on disability,22 non-medical use,23 conditions treated in
older adults,24 and rates of adverse events.25
However, in Australia, few studies have examined
person-level behaviours of people prescribed opioids,
prescribing patterns, patterns of use, or the outcomes
and costs associated with this use.26–28 In order to gain a
comprehensive understanding of these issues, we have
started a programme of research examining the patterns
and costs of PBS-subsidised opioid use, including
extramedical use in the Australian population. This
protocol summarises the scope of our programme.
Aims
The overall objective of this research programme is to
evaluate the patterns and costs of opioid use in
Australia. Specifically, we aim to:
1. Estimate monthly and annual utilisation and costs of
prescribed opioids, overall and according to individ-
ual opioid formulations and strengths.
2. Examine patterns of opioid use including initiation
of therapy, duration of treatment, concomitant use of
opioids and other therapy.
3. Examine patterns of extramedical opioid use based
on indicators including excess dosing, use of more
than one opioid concomitantly, doctor/pharmacy
shopping, and accelerated time to prescription refill.
METHODS AND ANALYSIS
Setting
Australia has a publically funded universal healthcare
system entitling all Australian citizens and permanent
residents to a range of subsidised health services.
This includes free treatment in public hospitals
(funded jointly by Commonwealth and State/Territory
governments), subsidised outpatient services including
consultations with medical and selected healthcare pro-
fessionals (funded by the Commonwealth’s Medicare
Benefits Scheme) and medicines prescribed in the com-
munity and private hospitals (funded by the PBS).
Medicines prescribed to public hospital inpatients are
covered primarily by hospital budgets.
Opioids of interest
The prescribed opioids of interest in this study include
opioid medicines belonging to the WHO’s Anatomical
Therapeutic Chemical classification system (http://www.
who.int/classifications/atcddd/en/) categories N02A,
N07B and R05D (table 1). We requested data for all formu-
lations and strengths of these medicines (individual PBS
item numbers). Methadone or buprenorphine may be pre-
scribed for the indication of opiate addiction or pain. For
the indication of opiate addiction, these medicines are
listed under the S100 Highly Specialised Drug Program
administered by the individual Australian states rather
than under the national funding system. We listed these
indications for completeness, however, the Department of
Human Services (DHS) do not record dispensings for
opioids dispensed under the state-based S100 program. All
records we obtain will be for the indication of pain.
Data of interest
Our research programme will be underpinned by access to
dispensing claims processed by the DHS, the PBS adminis-
tering body. Until recently, DHS only recorded dispensing
claims submitted for the payment of a PBS-subsidy. As
such, medicines costing less than the patient copayment
2 Degenhardt L, et al. BMJ Open 2015;4:e007030. doi:10.1136/bmjopen-2014-007030
Open Access
 on 4 N
ovem
ber 2018 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2014-007030 on 28 January 2015. D
ow
nloaded from
 
threshold were not ascertained in the collection. In effect,
low-cost medicines dispensed to beneficiaries with the
highest patient copayment threshold (referred to as
general beneficiaries) have been underascertained; this
issue does not impact on medicines dispensed to benefi-
ciaries with lower copayment thresholds (PBS concessional
beneficiaries). In April 2012, DHS began recording below
copayment prescriptions.
Our PBS-data requests have been structured in two
parts as described below:
Prevalent user cohort: comprising Australians dispensed
at least one opioid. This is a national cohort of all
persons (of any age) prescribed at least one opioid of
interest in a given calendar year (with the first year of
data being 2013). The cohort will provide contemporary
information about the prevalence of monthly and
annual prescribed opioid use across the Australian popu-
lation, including data from under copayment opioid pre-
scriptions. Data will be updated annually.
Incident user cohort: comprising Australians starting new
opioid therapy. This is a national cohort focusing on
persons dispensed at least one opioid in the period 1 July
2009 to 31 December 2013. Our observation period was
chosen as the DHS holds PBS data for a period of only
4 years and 6 months. The data set is updated daily and
when each additional day is added, the earliest date in
the data set is deleted. Therefore, our exact study period
is dependent on the date of extraction. This cohort will
be used to examine patterns of prescribed opioid use,
including extramedical use. Inclusion criteria are as
follows: (1) opioid naïve for at least 3 months prior to the
index prescription (see online supplementary appendix
A of details on the way in which this was operationalised);
(2) aged ≥18 years at the index prescription. We chose a
3-month wash-out period for cohort inclusion because it
was considered sufficient time to ensure that any new,
index prescriptions reflected a new ‘course’ of treatment
for a new or recurrent indication. It is possible that some
individuals will receive a new prescription under this def-
inition for an indication for which they have been treated
previously. However, we will also undertake sensitivity ana-
lyses by extending the period of non-use to 6 months.
This cohort will also be updated annually.
Tables 2 and 3 detail the variables requested from
DHS for the prevalent and incident user cohorts.
Statistical analysis
We will use best-practice pharmacoepidemiological
methods to explore prescribed opioid medicines use in
the two cohorts. The general approaches are detailed
below:
Table 2 Variables requested regarding cohort demographics
Variables Justification
Scrambled patient ID A unique sequence number enabling person-level analysis and linkage to PBS
data set
Month and year of birth To report demographics of cohort and used to stratify analyses according to
age group
Sex To report demographics of cohort and used to stratify analyses
Month and year of death (mm/yy) Date of death, in order to censor the follow-up time for each individual in the cohort
Postcode of residence mapped to
Statistical Local Area
Used to identify location of residence and map to indices of socioeconomic
disadvantage (ie, the Socio-Economic Indexes for Areas (SEIFA)*) and remoteness
(ie, the Accessibility/Remoteness Index of Australia (ARIA)†)
Geographic location of residence
according to the SA2
Used to identify geographic location of residence to map prescription rates and to
evaluate prescription rates according to key demographic characteristics
*Is a product developed by the ABS that ranks areas in Australia according to relative socioeconomic advantage and disadvantage. The
indexes are based on information from the 5-yearly census. Details can be found at: http://www.abs.gov.au/websitedbs/censushome.nsf/
home/seifa.
†The ABS’ Remoteness Areas classification. These are ‘Major Cities’, ‘Inner Regional’, ‘Outer Regional’, ‘Remote’ and ‘Very Remote’. Details
have been reported in ref. 54 55.
ABS, Australian Bureau of Statistics; ARIA, Accessibility/Remoteness Index of Australia; PBS, Pharmaceutical Benefits Scheme; SA2,
Statistical Area Level 2.
Table 1 Opioids of interest*
Medicine ATC code†
Oxycodone N02AA05, N02AA55
Tramadol N02AX02
Buprenorphine N02AE01, N07BC01, N07BC51
Fentanyl N02AB03
Morphine N02AA01
Hydromorphone N02AA03
Methadone N02AC52, N07BC02
Codeine N02BE51, N02AA59, N02AA79,
R05DA04‡
Tapentadol* N02AX06
*Tapentadol PBS-listed from 2014.
†ATC classification system is an internationally established
methodology endorsed by the WHO that is used to classify
medicines based on the organ or system on which they act, or
their therapeutic and chemical characteristics. Details of the ATC
classification system are found online at: http://www.who.int/
classifications/atcddd/en/.
‡Single ingredient codeine 30 mg tablets (opium alkaloids and
derivatives) are ATC coded to the respiratory system R05D and
not the nervous system N02A.
ATC, Anatomical Therapeutic Chemical; PBS, Pharmaceutical
Benefits Scheme.
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1. Utilisation and costs: we estimate the monthly and
annual prevalence and costs of opioid use overall
and according to individual opioid formulations and
strengths. Utilisation estimates will be based on
number of prescriptions, Defined Daily Dose (DDD)
per 1000 population per day or in oral morphine
equivalent mg.29 Analyses will be stratified according to
patient age, gender, location of residence and indices
of socioeconomic disadvantage. Data from the
Australian Bureau of Statistics will determine popula-
tion estimates for each subgroup of interest. Estimates
will also be presented using ESRI ArcGIS (a mapping
software programme). This will show overall national
patterns of use by geographical area of patient, pre-
scriber or dispensing pharmacy (eg, Statistical Local
Area, jurisdictionally), as well as graphical presentation
of variations in levels of use. Publicly available data on
the demographic characteristics of geographical areas
will be obtained from the Australian Bureau of
Statistics (age distribution, income, education and
unemployment).
2. Patterns of opioid use: we will examine patterns of use
in the following ways:
A. Median duration of opioid treatment: defined as
the time from the first opioid dispensing
record to the last dispensing record plus
30 days. These estimates can also detail differ-
ent courses of opioid therapy by accounting for
breaks in treatment of more than 60 days.
B. Dose escalation: we will estimate the average daily
dose of each opioid prescription dispensed
using the internationally recognised DDD
unit.30 At the individual level, we will calculate
the changes in average DDDs by prescription
and report the number of patients in whom
doses are increasing, and by what level, over
time.
C. Concomitant opioid and other concomitant medicines
use: we will investigate the concomitant use of
multiple opioids, in addition to the use of
opioids with other prescribed medicines, such
as benzodiazepines, antidepressants and anti-
psychotics. Concomitant use will generally be
defined as the observation of at least two dis-
pensing records from different medicines
within a specific time-frame of each other. The
rules will vary according to the therapy of inter-
est. Furthermore, we will identify individuals at
risk of potentially harmful drug–drug interac-
tions deemed to be clinically relevant in the
Table 3 Pharmaceutical Benefits Scheme (PBS) data on opioid dispensing (and other medication dispensing) history
Variables Description Justification
Scrambled patient
ID
A unique sequence number Enable person-level analysis and linkage to
sociodemographic data set
Month and year of
birth
Month and year when each person was born Determine age at time of dispensing. Also used as
cross-check with data in demographic file
Sex Sex Cross-check with data in demographic file
Date of supply Date medicine is dispensed Establish temporal relationship in dispensing
records
Item code A unique number which represents the dose form
and strength of the pharmaceutical item patients
receive
Identify medicines of different forms and strengths
ATC code Anatomical Therapeutic Chemical classification
code
Delineate between medicine types
Generic name Generic medication name Delineate between medicine types
Quantity
dispensed
Quantity of medicine dispensed Calculate defined daily dose and durations of
treatment
Original or repeat
prescription
A variable to distinguish between repeat or new
prescription
Understand pattern of treatment
Beneficiary level General beneficiary±safety net; concession card
holder±safety net
Identify level of entitlement and determine
comprehensiveness of data capture
PBS benefit Amount paid by the Australian government Determine the total cost incurred by the Australian
government to supply opioids in a given calendar
year
Prescriber
scrambled ID
A unique sequence number given to each
prescriber
Delineate between scripts written by different
doctors
Prescriber
location
Postcode mapped to Statistical Local Area Establish location of practice
Prescriber type Identifies primary specialty of the prescribing
doctor
Identify what type of doctors prescribe medicines of
interest
Pharmacy
scrambled ID
A unique sequence number given to each
dispensing pharmacy
Delineate between scripts dispensed at different
pharmacies
Pharmacy location Postcode mapped to Statistical Local Area Establish location of pharmacy
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literature and common drug information
resources.31–33 These will be examined using a
previously published approach34 overall, and
for specific population subgroups such as older
adults.
3. Extramedical use: indicators of extramedical opioid use
—we will adopt measures of extramedical use
described previously in the literature16 and report on
the rates of these patterns of extramedical use:
A. Excess dosing: defined as average daily dosing
outside guideline recommendations.35–37
B. Concomitant opioid use: as described above.36 38
C. Doctor shopping: opioid prescriptions written by
more than one doctor and dispensed within a
specific time-frame.14 39–45
D. Pharmacy shopping: dispensing opioid prescrip-
tions at more than one pharmacy within a spe-
cified time-frame.40–44
E. Accelerated prescription refill: repeated dispensing
of opioid prescriptions earlier than the estimate
of when the prescription is complete.36 37 46–49
The medication possession ratio and refill com-
pliance rate are measures which use administra-
tive data to assess adherence to medicines. We
have included accelerated prescription refill as
one of our measures of extramedical use.
We may restrict some of our analyses to concession
card-holding populations only, as not all opioid medi-
cines of interest are above the general beneficiary copay-
ment amount. Other medicines of interest including
benzodiazepines and psychotropic medicines such as
antidepressants, antipsychotics and central nervous
system stimulants, also fall below the general beneficiary
copayment. We will also undertake analyses with and
without persons dispensed cancer medicines to establish
how the inclusion of patients with cancer (who generally
receive significantly higher opioid doses than patients
without cancer) impacts on our estimates.
Data access approval
Data access has been approved by the DHS External
Review Evaluation Committee (MI0166). However, DHS
have recently advised that it may be necessary to restrict
our cohorts due to the considerable amount of data
they will be required to provide to us. For example, to
access the entire dispensing history of all people dis-
pensed an opioid in our incident user cohort, it has
been estimated that we would be provided with 40% of
the entire DHS data holdings. As such, our cohorts may
be restricted to a 10% random sample of the national
opioid user cohort.
Consent and privacy considerations
Use and Disclosure of Information: Commonwealth data are
governed under the Privacy Act 1988. Information
Privacy Principle (IPP) 2 under the Privacy Act 1988 pro-
vides that personal information should not be used or
disclosed for any purpose other than the primary
purpose of the collection. We have obtained approval
for the use of data for a secondary purpose: that of
research involving access to person-level information.
Under IPP2.1(d), use or disclosure for another purpose
is allowed if (A) it is necessary for research and it is
impracticable to gain consent AND (B) the use is in
accordance with the Section 95A guidelines (which pro-
vides a process to resolve the conflict that may arise
between the public interest in privacy and the public
interest in medical research).
Consent: The waiver for individual consent was approved
by the Population and Health Services Research Ethics
Committee in accordance with Section 95A of the
Commonwealth Privacy Act 1988. This was because:
▸ There were hundreds of thousands of people in the
cohort, so it was not possible or practical to obtain
consent because of the large study population.
▸ Obtaining consent would prejudice the scientific
value of the research due to the high participation
rates required for unbiased samples (at least 90%),50
and the Australian evidence about the sociodemo-
graphic differences between participants who consent
to data linkage research and those who do not.51
▸ We believe the public interest in this research out-
weighs the public interest in privacy protection. We
consider the benefits to be great and the risk to be
small. Currently we know little about the way in which
opioids are used in the real world marketplace. Our
research has the potential to address key issues such
as the risks and benefits of prescribing opioids in
Australia. These findings are likely to have national
and global significance.
We have minimised the risk to personal privacy by ensuring:
▸ Only researchers involved in data analysis will have
access to the data.
▸ Data will be securely stored at both sites (see below).
▸ The research team will not be in possession of any
personally identifying information. The files released
to the research team will not contain patients’ name,
rather a unique patient number will be generated by
the DHS staff.
Finally, all data will be presented in aggregated form
only and potentially identifiable information will not be
published. We will suppress data with small cell sizes.
Confidentiality of data and record retention
This is a collaborative project involving two research
teams, one based at the National Drug and Alcohol
Research Centre, The University of New South Wales,
Australia, and one based at the Faculty of Pharmacy, The
University of Sydney. To ensure consistency between the
analyses and research teams, decision rules will be devel-
oped in group meetings and all analyses will be con-
ducted in SAS so all relevant code can easily be shared
where necessary. The confidentiality of records will be
ensured by strict adherence to the study protocol in rela-
tion to access to, transfer and storage of study data.
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DISCUSSION
The rate of pharmaceutical opioid use is increasing
across the globe. However, the actual extent of such use
and extramedical use, is currently unknown. The
research programme outlined in this protocol will be the
first large-scale and nationally representative Australian
study to examine patterns of opioid use, including extra-
medical use, and the costs associated with this use.
Previously, PBS opioid dispensing data has typically been
analysed using aggregated data.5 9 This research will also
form the foundation of additional studies that can
examine the medical consequences of excessive prescrip-
tion opioid use. This type of research will be possible by
access to emergency department and hospitalisation plus
cause of death data.
From a clinical perspective, we will investigate common
opioid utilisation patterns and identify behaviour indica-
tive of extramedical use of opioids. Furthermore, we will
investigate the prevalence of potentially inappropriate
combinations of medicines prescribed with opioids, esti-
mating the number of individuals at risk of adverse drug
events due to potentially harmful drug–drug interactions.
Together, this information could provide a strong evi-
dence base for targeted future intervention programmes
to identify and treat high-risk individuals across Australia,
as well as form the basis of developing appropriate harm-
reduction strategies.
From a public health perspective, this research pro-
gramme will serve as an important first step to under-
standing and monitoring prescription opioid use, costs
and extramedical use of opioids, now and into the
future. Regulators across jurisdictions currently use dif-
ferent criteria for authorising long-term opioid therapy,
identifying at-risk patients and measuring potentially
problematic opioid use. Valid indicators are required to
identify the emergence of problems and provide infor-
mation that will allow the extent of the problem to be
monitored. Therefore, through the development of
robust proxies or indicators of extramedical opioid use,
this study will yield a useful surveillance tool for public
health authorities. Currently no universally accepted
indicators exist,52 and given the growing problem of
opioid use in Australia and globally, the indicators have
many potentially useful future applications.
Limitations
It is important to acknowledge several limitations of these
data. The first relates to the extent to which these data
reflect total opioid consumption in Australia. As noted
earlier, until 2012 only medicines reimbursed under the
PBS appear in the PBS collection. Items costing less than
the general beneficiary contribution did not receive a PBS
benefit and was not captured in the collection. This is par-
ticularly problematic for selected opioids. Private prescrip-
tions are also not included in the PBS collection, which
account for an unknown but potentially substantial
number of opioid prescriptions in Australia. Finally, these
data do not include opioids that are available in
pharmacies without a prescription (over-the-counter
opioids), which in Australia includes codeine, the unit
sales of which were more than 15 million in 2013
(personal communication, Gisev N, Nielsen S, Bruno R,
et al, 2014). Notwithstanding these limitations, the data we
will use certainly comprise the most detailed information
to hand about person-level patterns of opioid consump-
tion in Australia, permitting detailed estimates of clinical
issues that are of increasing community concern and great
public health importance.
Second, dispensing claims do not detail clinical infor-
mation, particularly that relating to indication for use.
This poses particular challenges given opioids are pre-
scribed at different doses depending on the nature of the
pain being managed; dosing for cancer and non-cancer
pain are likely to differ significantly. Given we will be pro-
vided with the PBS dispensing history of all opioid-treated
patients, we have the capacity to undertake sensitivity ana-
lyses excluding patients with a cancer treatment history.
However, this approach will not be definitive as cancer
medicines dispensing history is likely to be a specific but
not sensitive proxy for a cancer diagnosis.
The final limitation relates to the extent to which indi-
cators of extramedical use accurately reflect the
problem. However, we will develop our proxies through
a process of consultation of the extant literature,53 and
ongoing discussion with and feedback from expert clini-
cians in the fields of pain, cancer and addiction. We will
make ongoing efforts to generate valid indicators to the
fullest extent possible. Our use of sensitivity analyses to
check whether our conclusions are affected by variations
in definitions will also be a feature of our analyses.
Conclusions
This is a novel Australian research programme of opioid
use, costs and extramedical use at an individual level,
and with ongoing updates over time. This research has
the capability to contribute significantly to pharmaceut-
ical policy within Australia and globally.
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